In May 2022, under the auspices of WHO’s COVID-19 Technology Access Pool (C-TAP), MPP signed two licensing agreements with the United States National Institutes of Health (NIH) for the development of 11 innovative therapeutics, early-stage vaccines and diagnostic tools for COVID-19.

Among these COVID-19 technologies is a diagnostic:

RNASEH-Assisted Detection Assay for RNA:

NCI researchers developed a diagnostic methodology that can detect specific RNA sequences in less than 3 hours and does not require the expensive thermocycler instrument needed for PCR tests. The technology uses low-cost reagents and has potential for point-of-care applications for detection of cellular or viral RNA.

MPP invites interested developers anywhere in the world to express their interest in obtaining a sublicence for any of these technologies by submitting an e-mail to providing as much detail as possible as to what the developer intends to do with a sublicence.

Country List